Abstract:ABSTRACTThe interaction between Receptor Activator of NF‐κB Ligand (RANKL) and its receptor RANK is essential for the differentiation and bone resorbing capacity of the osteoclast. Osteoprotegerin (OPG), a soluble homodimer, acts as a decoy receptor for RANKL and thus inhibits osteoclastogenesis. An imbalance in the RANKL/RANK/OPG axis, with decreased OPG and/or increased RANKL, is associated with diseases that favor bone loss, including osteoporosis. Recently, we established a yeast surface display system and screened libraries of randomly mutated RANKL proteins to identify mutations that abolish binding to OPG while preserving recognition of RANK. These efforts yielded several RANKL variants possessing substantially higher affinity for RANK compared to their wild‐type (WT) counterpart. Using recombinant RANKL mutant proteins, we find those with increased affinity for RANK produce more robust signaling in osteoclast lineage cells and have greater osteoclastogenic potential. Our results are the first to document gain of function RANKL mutations. They indicate that the physiological RANKL/RANK interaction is not optimized for maximal signaling and function, perhaps reflecting the need to maintain receptor specificity within the tumor necrosis factor superfamily (TNFSF). Instead, we find, a biphasic relationship exists between RANKL/RANK affinity and osteoclastogenic capacity. In our panel of RANKL variants, this relationship is driven entirely by manipulation of the kinetic off‐rate. Our structure‐based and yeast surface display‐derived insights into manipulating this critical signaling axis may aid in the design of novel anti‐resorptive therapies as well as provide a paradigm for design of other receptor‐specific TNF superfamily ligand variants. J. Cell. Biochem. 116: 2476–2483, 2015. © 2015 Wiley Periodicals, Inc.

Disabling of Receptor Activator of Nuclear Factor-κB (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo*

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Structure-based Development of an Osteoprotegerin-Like Glycopeptide That Blocks RANKL/RANK Interactions and Reduces Ovariectomy-Induced Bone Loss in Mice.

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

Notopterol Attenuates Estrogen Deficiency-Induced Osteoporosis <i>via</i> Repressing RANKL Signaling and Reactive Oxygen Species

Recombinant Receptor Activator of Nuclear Factor Κb Exhibits More Marked Inhibitory Effects on Osteoclasts Compared with Recombinant Osteoprotegerin in Vitro and in Vivo.

Recombinant Soluble Receptor Activator of Nuclear Factor-Kappab Inhibits Parathyroid Hormone-Induced Osteoclastogenesis in Vitro.

Correlating Rank Ligand/Rank Binding Kinetics with Osteoclast Formation and Function

A TrkB Agonist Prodrug Prevents Bone Loss Via Inhibiting Asparagine Endopeptidase and Increasing Osteoprotegerin

TNF-family member Receptor Activator of NF-κB (RANK) and RANK-Ligand (RANKL) in bone remodelling

A Novel Anti-Osteoporotic Agent That Protects Against Postmenopausal Bone Loss by Regulating Bone Formation and Bone Resorption.

Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption

A Novel Diterpenoid Suppresses Osteoclastogenesis and Promotes Osteogenesis by Inhibiting Ifrd1-Mediated and IκBα-Mediated p65 Nuclear Translocation.

R13, a TrkB Agonist Prodrug, Inhibits Asparagine Endopeptidase (AEP) and Increases Osteoprotegerin (OPG), Preventing Bone Loss

Crystal Structure of Human RANKL Complexed with Its Decoy Receptor Osteoprotegerin.

Osteoprotegerin secretion and its inhibition by RANKL in osteoblastic cells visualized using bioluminescence imaging

Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism

A TNF receptor loop peptide mimic blocks RANK ligand–induced signaling, bone resorption, and bone loss

Identification of novel RANKL inhibitors through in silico analysis

Tumor Necrosis Factor Receptor Family Member Rank Mediates Osteoclast Differentiation And Activation Induced By Osteoprotegerin Ligand

Murine Rank Protein'S Inhibition of Bone Resorption